Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplant.

Saad A, Taneja A, Di Stasi A, Sarmad R, Kukkamalla R, Costa L, Salzman D, Innis-Shelton R, Chewning JH, Meredith RF, Hauptfeld V, Langford S, Plessala K, Bhatia R, Lamb LS, Mineishi S.

Bone Marrow Transplant. 2018 Oct;53(10):1345-1348. doi: 10.1038/s41409-018-0185-6. Epub 2018 May 4. No abstract available.

PMID:
29728698
2.

Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab.

Meredith RF, Torgue JJ, Rozgaja TA, Banaga EP, Bunch PW, Alvarez RD, Straughn JM Jr, Dobelbower MC, Lowy AM.

Am J Clin Oncol. 2018 Jul;41(7):716-721. doi: 10.1097/COC.0000000000000353.

3.

A phase 2 study of radiosurgery and temozolomide for patients with 1 to 4 brain metastases.

Fiveash JB, Arafat WO, Naoum GE, Guthrie BL, Sawrie SM, Spencer SA, Meredith RF, Markert JM, Conry RM, Nabors BL.

Adv Radiat Oncol. 2016 Apr 1;1(2):83-88. doi: 10.1016/j.adro.2016.03.004. eCollection 2016 Apr-Jun.

4.

MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy.

Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sjögreen-Gleisner K; SNMMI MIRD Committee, Bolch WE, Brill AB, Fahey F, Fisher DR, Hobbs R, Howell RW, Meredith RF, Sgouros G, Zanzonico P; EANM Dosimetry Committee, Bacher K, Chiesa C, Flux G, Lassmann M, Strigari L, Walrand S.

J Nucl Med. 2016 Jan;57(1):151-62. doi: 10.2967/jnumed.115.159012. Epub 2015 Oct 15.

5.

Pazopanib combined with radiation: in vivo model of interaction.

Meredith RF, Raisch KP, Bonner JA, Buchsbaum DJ, Grizzle WE, Li Y, Spencer SA.

Cancer Biother Radiopharm. 2014 Aug;29(6):247-50. doi: 10.1089/cbr.2013.1583. Epub 2014 Jun 19.

PMID:
24945464
6.

Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients.

Meredith RF, Torgue J, Azure MT, Shen S, Saddekni S, Banaga E, Carlise R, Bunch P, Yoder D, Alvarez R.

Cancer Biother Radiopharm. 2014 Feb;29(1):12-7. doi: 10.1089/cbr.2013.1531. Epub 2013 Nov 14.

7.

MIRD pamphlet No. 24: Guidelines for quantitative 131I SPECT in dosimetry applications.

Dewaraja YK, Ljungberg M, Green AJ, Zanzonico PB, Frey EC; SNMMI MIRD Committee, Bolch WE, Brill AB, Dunphy M, Fisher DR, Howell RW, Meredith RF, Sgouros G, Wessels BW.

J Nucl Med. 2013 Dec;54(12):2182-8. doi: 10.2967/jnumed.113.122390. Epub 2013 Oct 15.

8.

Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma.

Vaklavas C, Meredith RF, Shen S, Knox SJ, Micallef IN, Shah JJ, LoBuglio AF, Forero-Torres A.

Cancer Biother Radiopharm. 2013 Jun;28(5):370-9. doi: 10.1089/cbr.2012.1387. Epub 2013 Mar 26.

PMID:
23530878
9.

Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma.

Shen S, Forero A, Meredith RF, LoBuglio AF.

Cancer Biother Radiopharm. 2011 Feb;26(1):127-33. doi: 10.1089/cbr.2010.0864.

PMID:
21355784
10.

Renal dosimetry.

Wessels BW, Dale RG, Cremonesi M, Meredith RF, Green AJ, Brill B, Bolch WE, Sgouros G, Thomas SR.

Cancer Biother Radiopharm. 2010 Oct;25(5):597-9. doi: 10.1089/cbr.2010.0867. Epub 2010 Sep 28. No abstract available.

PMID:
20874486
11.

Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.

Forero-Torres A, Saleh MN, Galleshaw JA, Jones CF, Shah JJ, Percent IJ, Nabell LM, Carpenter JT, Falkson CI, Krontiras H, Urist MM, Bland KI, De Los Santos JF, Meredith RF, Caterinicchia V, Bernreuter WK, O'Malley JP, Li Y, LoBuglio AF.

Clin Breast Cancer. 2010 Aug 1;10(4):275-80. doi: 10.3816/CBC.2010.n.035.

12.

MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.

Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, Brill AB, Song H, Howell RW, Akabani G; SNM MIRD Committee, Bolch WE, Brill AB, Fisher DR, Howell RW, Meredith RF, Sgouros G, Wessels BW, Zanzonico PB.

J Nucl Med. 2010 Feb;51(2):311-28. doi: 10.2967/jnumed.108.058651. Epub 2010 Jan 15.

13.

Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.

Shen S, Forero A, Meredith RF, Shah JJ, Knox SJ, Wiseman GA, Usrey ME, Lobuglio AF.

J Nucl Med. 2010 Jan;51(1):150-7. doi: 10.2967/jnumed.109.066597. Epub 2009 Dec 15.

14.

Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy.

Murphy BA, Beaumont JL, Isitt J, Garden AS, Gwede CK, Trotti AM, Meredith RF, Epstein JB, Le QT, Brizel DM, Bellm LA, Wells N, Cella D.

J Pain Symptom Manage. 2009 Oct;38(4):522-32. doi: 10.1016/j.jpainsymman.2008.12.004. Epub 2009 Jul 15.

PMID:
19608377
15.

Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck.

Caudell JJ, Schaner PE, Desmond RA, Meredith RF, Spencer SA, Bonner JA.

Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):403-9. doi: 10.1016/j.ijrobp.2009.02.017. Epub 2009 May 19.

PMID:
19467801
16.

Margin on gross tumor volume and risk of local recurrence in head-and-neck cancer.

Caudell JJ, Meredith RF, Spencer SA, Keene KS, Dobelbower MC, Bonner JA.

Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):164-8. doi: 10.1016/j.ijrobp.2009.01.037.

PMID:
19386438
17.

MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan.

Fisher DR, Shen S, Meredith RF.

J Nucl Med. 2009 Apr;50(4):644-52. doi: 10.2967/jnumed.108.057331. Epub 2009 Mar 16. Erratum in: J Nucl Med. 2012 Apr;53(4):646.

18.

MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.

Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF, Green AJ, Bouchet LG, Brill AB, Bolch WE, Sgouros G, Thomas SR.

J Nucl Med. 2008 Nov;49(11):1884-99. doi: 10.2967/jnumed.108.053173. Epub 2008 Oct 16. Erratum in: J Nucl Med. 2011 Sep;52(9):1498.

19.

Targeted radionuclide therapy.

Williams LE, DeNardo GL, Meredith RF.

Med Phys. 2008 Jul;35(7):3062-8.

20.

Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer.

Caudell JJ, Schaner PE, Meredith RF, Locher JL, Nabell LM, Carroll WR, Magnuson JS, Spencer SA, Bonner JA.

Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):410-5. doi: 10.1016/j.ijrobp.2008.04.048. Epub 2008 Jul 16.

PMID:
18635320
21.

Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.

Brizel DM, Murphy BA, Rosenthal DI, Pandya KJ, Glück S, Brizel HE, Meredith RF, Berger D, Chen MG, Mendenhall W.

J Clin Oncol. 2008 May 20;26(15):2489-96. doi: 10.1200/JCO.2007.13.7349.

PMID:
18487568
22.

Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment.

Caudell JJ, Sawrie SM, Spencer SA, Desmond RA, Carroll WR, Peters GE, Nabell LM, Meredith RF, Bonner JA.

Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):676-81. doi: 10.1016/j.ijrobp.2007.10.040. Epub 2008 Mar 20.

PMID:
18355979
23.

A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebrae.

Meredith RF, Shen S, Forero A, LoBuglio A.

J Nucl Med. 2008 Feb;49(2):279-84. doi: 10.2967/jnumed.107.045021. Epub 2008 Jan 16.

24.

Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer.

Meredith RF, Buchsbaum DJ, Alvarez RD, LoBuglio AF.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5643s-5645s. Review.

25.

Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone.

Sawrie SM, Guthrie BL, Spencer SA, Nordal RA, Meredith RF, Markert JM, Cloud GA, Fiveash JB.

Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):181-6. Epub 2007 Sep 4.

PMID:
17768015
26.

Microvessel density >or=60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: results of a correlative study from the Radiation Therapy Oncology Group (RTOG) 90-03 Trial.

Calvin DP, Hammond ME, Pajak TF, Trotti AM, Meredith RF, Rotman M, Jones CU, Byhardt RW, Demas WF, Ang KK, Fu KK; Radiation Therapy Oncology Group 90-03 Trial.

Am J Clin Oncol. 2007 Aug;30(4):406-19.

PMID:
17762442
27.

Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.

Hartsell WF, Scott CB, Dundas GS, Mohiuddin M, Meredith RF, Rubin P, Weigensberg IJ.

Am J Clin Oncol. 2007 Aug;30(4):368-76.

PMID:
17762437
28.

Systemic Targeted Radionuclide Therapy symposium introduction.

Meredith RF.

Int J Radiat Oncol Biol Phys. 2006;66(2 Suppl):S7. No abstract available.

PMID:
16979444
29.

Pretargeted radioimmunotherapy.

Meredith RF, Buchsbaum DJ.

Int J Radiat Oncol Biol Phys. 2006;66(2 Suppl):S57-9. Review.

PMID:
16979441
30.

Overview of dosimetry for Systemic Targeted Radionuclide Therapy (STaRT).

Wessels BW, Syh JH, Meredith RF.

Int J Radiat Oncol Biol Phys. 2006;66(2 Suppl):S39-45. Review.

PMID:
16979438
31.

Logistics of therapy with the ibritumomab tiuxetan regimen.

Meredith RF.

Int J Radiat Oncol Biol Phys. 2006;66(2 Suppl):S35-8. Review.

PMID:
16979437
32.

Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.

Meredith RF.

Int J Radiat Oncol Biol Phys. 2006;66(2 Suppl):S23-9. Review.

PMID:
16979435
33.

Summary of systemic targeted radionuclide therapy symposium.

Meredith RF.

Int J Radiat Oncol Biol Phys. 2006;66(2 Suppl):S2-3. No abstract available.

PMID:
16979434
34.

Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.

Meredith RF, Knox SJ.

Int J Radiat Oncol Biol Phys. 2006;66(2 Suppl):S15-22. Review.

PMID:
16979433
35.

166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.

Breitz HB, Wendt RE 3rd, Stabin MS, Shen S, Erwin WD, Rajendran JG, Eary JF, Durack L, Delpassand E, Martin W, Meredith RF.

J Nucl Med. 2006 Mar;47(3):534-42.

36.

Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration.

Forero A, Meredith RF, Khazaeli MB, Shen S, Grizzle WE, Carey D, Busby E, LoBuglio AF, Robert F.

Cancer Biother Radiopharm. 2005 Oct;20(5):467-78.

PMID:
16248762
37.

Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.

Forero-Torres A, Shen S, Breitz H, Sims RB, Axworthy DB, Khazaeli MB, Chen KH, Percent I, Besh S, LoBuglio AF, Meredith RF.

Cancer Biother Radiopharm. 2005 Aug;20(4):379-90.

PMID:
16114986
38.

Blood-based red marrow dosimetry: where's the beef?

Siegel JA, Sparks RB, Sharkey RM, Wessels BW, Bolch WE, Bouchet LG, Breitz HB, Meredith RF, Sgouros G, Stabin MG.

J Nucl Med. 2005 Aug;46(8):1404-6; author reply 1405-6. No abstract available.

39.

Clinically useful marrow dosimetry for targeted radionuclide therapy.

Shen S, Meredith RF.

Cancer Biother Radiopharm. 2005 Apr;20(2):119-22. No abstract available.

PMID:
15869444
40.

Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.

Shen S, Forero A, LoBuglio AF, Breitz H, Khazaeli MB, Fisher DR, Wang W, Meredith RF.

J Nucl Med. 2005 Apr;46(4):642-51.

41.

Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.

Wessels BW, Bolch WE, Bouchet LG, Breitz HB, Denardo GL, Meredith RF, Stabin MG, Sgouros G; American Association of Physicists in Medicine.

J Nucl Med. 2004 Oct;45(10):1725-33.

42.

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.

Forero A, Weiden PL, Vose JM, Knox SJ, LoBuglio AF, Hankins J, Goris ML, Picozzi VJ, Axworthy DB, Breitz HB, Sims RB, Ghalie RG, Shen S, Meredith RF.

Blood. 2004 Jul 1;104(1):227-36. Epub 2004 Mar 2.

PMID:
14996706
43.

A novel monoclonal antibody design for radioimmunotherapy.

Forero A, Meredith RF, Khazaeli MB, Carpenter DM, Shen S, Thornton J, Schlom J, LoBuglio AF.

Cancer Biother Radiopharm. 2003 Oct;18(5):751-9.

PMID:
14629823
44.

P105 as a prognostic indicator in patients irradiated for locally advanced head-and-neck cancer: a clinical/laboratory correlative analysis of RTOG-9003.

Hammond E, Berkey BA, Fu KK, Trotti A, Meredith RF, Jones CU, Byhardt R, Horwitz EM, Ang KK.

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):683-92.

PMID:
14529772
45.

Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy.

Shen S, Meredith RF, Duan J, Brezovich I, Khazaeli MB, LoBuglio AF.

Cancer Biother Radiopharm. 2003 Apr;18(2):209-15.

PMID:
12804046
46.

Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer--RTOG 97-09.

Fisher J, Scott C, Scarantino CW, Leveque FG, White RL, Rotman M, Hodson DI, Meredith RF, Foote R, Bachman DG, Lee N.

Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):832-6.

PMID:
12788192
47.

A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.

Alvarez RD, Huh WK, Khazaeli MB, Meredith RF, Partridge EE, Kilgore LC, Grizzle WE, Shen S, Austin JM, Barnes MN, Carey D, Schlom J, LoBuglio AF.

Clin Cancer Res. 2002 Sep;8(9):2806-11.

48.

Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy.

Shen S, Meredith RF, Duan J, Macey DJ, Khazaeli MB, Robert F, LoBuglio AF.

J Nucl Med. 2002 Sep;43(9):1245-53.

49.

Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial.

Robert F, Spencer SA, Childs HA 3rd, Zhang R, Meredith RF, Wheeler RH, Hawkins MH, Carey D.

Lung Cancer. 2002 Aug;37(2):189-99.

PMID:
12140142
50.

Rationales, evidence, and design considerations for fractionated radioimmunotherapy.

DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O'Donoghue JA, Sgouros G, Humm JL, DeNardo SJ.

Cancer. 2002 Feb 15;94(4 Suppl):1332-48.

Supplemental Content

Loading ...
Support Center